TP53 and cancer: The association of p53 mutations with immunosuppression in CRC, specifically COAD, has been shown in another study, where the authors demonstrated that tumors with p53 mutations had significantly decreased antitumor immune signatures, including a lower ratio of pro-/anti-inflammatory cytokines than cancers harboring wild-type p53 [109].